NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis $0.28 -0.01 (-1.95%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.28 +0.00 (+0.36%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About GeoVax Labs Stock (NASDAQ:GOVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GeoVax Labs alerts:Sign Up Key Stats Today's Range$0.27▼$0.3050-Day Range$0.28▼$0.7752-Week Range$0.27▼$15.75Volume233,073 shsAverage Volume903,284 shsMarket Capitalization$2.07 millionP/E RatioN/ADividend YieldN/APrice Target$150.00Consensus RatingHold Company Overview GeoVax Labs, Inc. is a biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based primarily on a vaccine platform that combines a modified vaccinia Ankara (MVA) viral vector with virus-like particles (VLPs) to stimulate both antibody and cellular immune responses. GeoVax’s development programs have included GEO-CM04S1, a next-generation COVID-19 vaccine candidate; GOVX-B11, an investigational HIV vaccine designed to generate broadly protective immune responses; and GOVX-CHIKV, a vaccine candidate targeting chikungunya virus. The company has also pursued additional vaccine and immunotherapy applications through collaborations and government-supported research programs. Headquartered in the Atlanta, Georgia, area, GeoVax has advanced its candidates through collaborations with organizations including the National Institutes of Health and other public-sector and research partners. The company’s programs remain subject to clinical development and regulatory review, and their availability and indications may change as research progresses.AI Generated. May Contain Errors. Read More GeoVax Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreGOVX MarketRank™: GeoVax Labs scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingGeoVax Labs has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialGeoVax Labs has a consensus price target of $150.00, representing about 53,280.8% upside from its current price of $0.28.Amount of Analyst CoverageGeoVax Labs has only been the subject of 2 research reports in the past 90 days.Read more about GeoVax Labs' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($4.94) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeoVax Labs is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeoVax Labs is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GeoVax Labs' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.83% of the float of GeoVax Labs has been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 1.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 43.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.16 News SentimentGeoVax Labs has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GeoVax Labs this week, compared to 3 articles on an average week.Search Interest3 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have not sold or bought any company stock.Percentage Held by Insiders0.22% of the stock of GeoVax Labs is held by insiders.Percentage Held by Institutions6.09% of the stock of GeoVax Labs is held by institutions.Read more about GeoVax Labs' insider trading history. Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GOVX Stock News HeadlinesGeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026October 6, 2026 | theglobeandmail.comGeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United StatesSeptember 29, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 10 at 1:00 AM | Porter & Company (Ad)GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical ModelsSeptember 21, 2026 | finance.yahoo.comGeoVax Confirms Bundibugyo Ebola Vaccine ConstructSeptember 16, 2026 | finance.yahoo.comGeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 TrialSeptember 14, 2026 | finance.yahoo.comGeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic PrioritiesSeptember 10, 2026 | finance.yahoo.comGeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global SupplySeptember 9, 2026 | finance.yahoo.comSee More Headlines GOVX Stock Analysis - Frequently Asked Questions How have GOVX shares performed this year? GeoVax Labs' stock was trading at $4.2750 at the start of the year. Since then, GOVX stock has decreased by 93.4% and is now trading at $0.2810. How were GeoVax Labs' earnings last quarter? GeoVax Labs Inc. (NASDAQ:GOVX) issued its quarterly earnings data on Monday, July, 27th. The company reported ($0.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.16) by $1.19. When did GeoVax Labs' stock split? GeoVax Labs's stock reverse split on the morning of Monday, January 12th 2026.The 1-25 reverse split was announced on Thursday, January 8th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 9th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeoVax Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeoVax Labs investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Ovid Therapeutics (OVID). Company Calendar Last Earnings7/27/2026Today10/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GOVX's financial health is in the Red zone, according to TradeSmith. GOVX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GOVX CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees19Year Founded2001Price Target and Rating Average Price Target for GeoVax Labs$150.00 High Price Target$150.00 Low Price Target$150.00 Potential Upside/Downside+53,280.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($11.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-743.64% Return on Assets-394.74% Debt Debt-to-Equity RatioN/A Current Ratio1.54 Quick Ratio1.54 Sales & Book Value Annual Sales$2.49 million Price / Sales0.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book0.13Miscellaneous Outstanding Shares7,370,000Free Float7,353,000Market Cap$2.07 million OptionableNot Optionable Beta3.69 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GOVX) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
